NB

NovaBay Pharmaceuticals IncNYSE-MKT NBY Stock Report

Last reporting period 31 Mar, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

0.002

Micro

Exchange

XASE - Nyse MKT LLC

NBY Stock Analysis

NB

Uncovered

NovaBay Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-30/100

Low score

Market cap $B

0.002

Dividend yield

Shares outstanding

2.035 B

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 29 full-time employees. The company went IPO on 2007-10-26. The firm's lead product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have antimicrobial properties as it removes foreign material, such as microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with its form of hypochlorous acid and is cleared by the United States Food and Drug Administration (FDA) for sale in the United States. Its other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress and the i-Chek. Avenova Spray is available both over-the-counter and as a prescription. Avenova Spray is also available at optometrists and ophthalmologists offices; at national pharmacy chains across all over 50 states, and through its Partner Pharmacy Program.

View Section: Eyestock Rating